ReviewThe Lancet. Infectious diseases2017
Human schistosomiasis in the post mass drug administration era.
Review in The Lancet. Infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 4 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Malaria and Helminthic Co-Infection during Pregnancy in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- An update on non-invasive urine diagnostics for human-infecting parasitic helminths: what more could be done and how?Parasitology · 2020Pooled it
- MICHELINdb: a web-based tool for mining of helminth-microbiota interaction datasets, and a meta-analysis of current research.Microbiome · 2020Pooled it
- Population level changes in schistosome-specific antibody levels following chemotherapy.Parasite immunology · 2019Pooled it
- Schistosoma mansoni treatment reduces HIV entry into cervical CD4+ T cells and induces IFN-I pathways.Nature communications · 2019Trial
- Praziquantel for the treatment of schistosomiasis during human pregnancy.Bulletin of the World Health Organization · 2018Trial
- In vivo assessment of anti-helminthic and anti-inflammatory effects of Fucoidan on Schistosoma mansoni immature stages.Scientific reports · 2026Article
- Ultrasound evaluation of urinary tract morbidity in adults living in a Schistosoma haematobium endemic region in Mozambique.BMC infectious diseases · 2026Article
- Persistent Burden of Schistosomiasis in South Africa: A National Laboratory-Based Analysis, 2019-2024.Tropical medicine and infectious disease · 2026Article
- Factors affecting detection and quantification of Schistosoma haematobium eggs in pooled urine samples.PLoS neglected tropical diseases · 2026Article
- The human immunome in the post-schistosomiasis mass drug administration era.PLoS neglected tropical diseases · 2026Review
- Evaluation of surveillance-response interventions for Schistosoma haematobium elimination on Pemba Island, Tanzania: A 4-year intervention study with repeated cross-sectional surveys.PLoS neglected tropical diseases · 2026Article
- Confronting the known unknown: historical lessons and future strategies for Disease X.Frontiers in public health · 2026Review
- An automated end-to-end system for schistosome viability assessment to accelerate anti-schistosomal drug discovery.PLoS neglected tropical diseases · 2026Article
- Future climate and demographic changes will almost double the risk of schistosomiasis transmission in the Lake Victoria Basin.One health (Amsterdam, Netherlands) · 2025Review
- Protein palmitoylation in hepatic diseases: Functional insights and therapeutic strategies.Journal of advanced research · 2025Review
- Potential biomarker and composite efficacy readout for human clinical trials of schistosomiasis vaccine in Africa.Scientific reports · 2025Article
- A model predicting the 6-year all cause mortality of patients with advanced schistosomiasis after discharge: Derived from a large population-based cohort study.PLoS neglected tropical diseases · 2025Article
- Priority knowledge gaps for schistosomiasis research and development in the World Health Organization Africa Region.Infectious diseases of poverty · 2025Article
- RNAi screening of uncharacterized genes identifies promising druggable targets in Schistosoma japonicum.PLoS pathogens · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
Profound changes are occurring in the epidemiology of schistosomiasis, a neglected tropical disease caused by a chronic infection with parasitic helminths of the genus Schistosoma. Schistosomiasis currently affects 240 million people worldwide, mostly in sub-Saharan Africa. The advent and proliferation of mass drug administration (MDA) programmes using the drug praziquantel is resulting in substantial increases in the number of people, mainly children aged 6-14 years, being effectively treated, approaching the point where most people in endemic areas will receive one or more treatments during their lifetimes. Praziquantel treatment not only cures infection but also frees the host from the powerful immunomodulatory action of the parasites. The treatment simultaneously enhances exposure to key parasite antigens, accelerating the development of protective acquired immunity, which would take many years to develop naturally. At a population level, these changes constitute a substantial alteration to schistosome ecology in that the parasites are more likely to be exposed not only to praziquantel directly but also to hosts with altered immune phenotypes. Here, we consider the consequences of this for schistosome biology, immunoepidemiology, and public health. We anticipate that there could be substantial effects on chronic pathology, natural immunity, vaccine development strategies, immune disorders, and drug efficacy. This makes for a complex picture that will only become apparent over decades. We recommend careful monitoring and assessment to accompany the roll-out of MDA programmes to ensure that the considerable health benefits to populations are achieved and sustained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.